Insider Trades91 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Sell | BDX | Bilal Muhsin | EVP & President Connected Care | 1,935 | $158.08 | $43.6B | -25.77% | +12.89% | $305.9K | -4.47% | — | Stalk |
| Jun 26, 2026 | Sell | BDX | Michael Feld | EVP, Chief Revenue Officer | 75 | $152.80 | $43.6B | -25.77% | +12.89% | $11.5K | -0.36% | — | Stalk |
| Jun 24, 2026 | Sell | BDX | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | 1,100 | $145.66 | $43.6B | -25.77% | +12.89% | $160.2K | -7.71% | — | Stalk |
| Jun 10, 2026 | Sell | BDX | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | 1,100 | $151.48 | $43.6B | -25.77% | +12.89% | $166.6K | -7.16% | — | Stalk |
| Jun 1, 2026 | Buy | BDX | Thomas E Jr Polen | Chairman, CEO and President | 22,973 | $128.59 | $43.6B | -25.77% | +12.89% | $3.0M | +7.99% | — | Stalk |
| May 26, 2026 | Sell | BDX | Michael Feld | EVP, Chief Revenue Officer | 75 | $147.35 | $43.6B | -25.77% | +12.89% | $11.1K | -0.35% | — | Stalk |
| Apr 27, 2026 | Sell | BDX | Michael Feld | EVP, Chief Revenue Officer | 74 | $151.94 | $43.6B | -25.77% | +12.89% | $11.2K | -0.35% | — | Stalk |
| Apr 6, 2026 | Sell | BDX | Shana Carol Neal | EVP and Chief People Officer | 1,146 | $155.32 | $43.6B | -25.77% | +12.89% | $178.0K | -4.56% | — | Stalk |
| Mar 26, 2026 | Sell | BDX | Michael Feld | EVP, Chief Revenue Officer | 75 | $156.83 | $43.6B | -25.77% | +12.89% | $11.8K | -0.35% | — | Stalk |
| Feb 26, 2026 | Sell | BDX | Michael Feld | EVP, Chief Revenue Officer | 75 | $181.84 | $43.6B | -25.77% | +12.89% | $13.6K | -0.35% | — | Stalk |
| Jan 26, 2026 | Sell | BDX | Michael Feld | EVP, CRO & Pres. Life Sciences | 75 | $202.73 | $43.6B | -25.77% | +12.89% | $15.2K | -0.45% | — | Stalk |
| Jan 21, 2026 | Sell | BDX | Pamela L. Spikner | SVP Controller & CAO | 84 | $206.18 | $43.6B | -25.77% | +12.89% | $17.3K | -4.38% | — | Stalk |
| Jan 15, 2026 | Buy | BDX | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | 4,664 | $181.56 | $43.6B | -25.77% | +12.89% | $846.8K | +3.62% | — | Stalk |
| Jan 3, 2026 | Sell | BDX | David Shan | EVP and Chief ISC Officer | 44 | $194.94 | $43.6B | -25.77% | +12.89% | $8.6K | -0.49% | — | Stalk |
| Dec 26, 2025 | Sell | BDX | Michael Feld | EVP, CRO & Pres. Life Sciences | 74 | $196.08 | $43.6B | -25.77% | +12.89% | $14.5K | -0.45% | — | Stalk |
| Dec 17, 2025 | Sell | BDX | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | 629 | $196.03 | $43.6B | -25.77% | +12.89% | $123.3K | -4.58% | — | Stalk |
| Dec 1, 2025 | Sell | BDX | Michael Feld | EVP, CRO & Pres. Life Sciences | 75 | $193.36 | $43.6B | -25.77% | +12.89% | $14.5K | -0.45% | — | Stalk |
| Nov 26, 2025 | Sell | BDX | David Shan | EVP and Chief ISC Officer | 134 | $193.90 | $43.6B | -25.77% | +12.89% | $26.0K | -1.47% | — | Stalk |
| Nov 26, 2025 | Sell | BDX | Roland Goette | EVP and President, EMEA | 138 | $193.90 | $43.6B | -25.77% | +12.89% | $26.8K | -0.79% | — | Stalk |
| Nov 26, 2025 | Sell | BDX | Michael Feld | EVP, CRO & Pres. Life Sciences | 419 | $193.90 | $43.6B | -25.77% | +12.89% | $81.2K | -2.45% | — | Stalk |
| Nov 26, 2025 | Sell | BDX | Richard Byrd | EVP & President Interventional | 1,719 | $193.90 | $43.6B | -25.77% | +12.89% | $333.3K | -11.04% | — | Stalk |
| Nov 26, 2025 | Sell | BDX | Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | 1,769 | $193.90 | $43.6B | -25.77% | +12.89% | $343.0K | -11.41% | — | Stalk |
| Nov 26, 2025 | Sell | BDX | Shana Carol Neal | EVP and Chief People Officer | 2,454 | $193.90 | $43.6B | -25.77% | +12.89% | $475.8K | -10.32% | — | Stalk |
| Nov 26, 2025 | Sell | BDX | Christopher Delorefice | EVP & Chief Financial Officer | 4,245 | $193.90 | $43.6B | -25.77% | +12.89% | $823.1K | -15.59% | — | Stalk |
| Nov 26, 2025 | Sell | BDX | Thomas E Jr Polen | Chairman, CEO and President | 17,421 | $193.90 | $43.6B | -25.77% | +12.89% | $3.4M | -6.04% | — | Stalk |
| Oct 27, 2025 | Sell | BDX | Michael Feld | EVP & President, Life Sciences | 57 | $186.01 | $43.6B | -25.77% | +12.89% | $10.6K | -0.69% | — | Stalk |
| Sep 26, 2025 | Sell | BDX | Michael Feld | EVP & President, Life Sciences | 58 | $181.03 | $43.6B | -25.77% | +12.89% | $10.5K | -0.69% | — | Stalk |
| Sep 1, 2025 | Sell | BDX | Richard Byrd | EVP & President Interventional | 216 | $192.98 | $43.6B | -25.77% | +12.89% | $41.7K | -3.11% | — | Stalk |
| Sep 1, 2025 | Sell | BDX | Christopher Delorefice | EVP & Chief Financial Officer | 278 | $192.98 | $43.6B | -25.77% | +12.89% | $53.6K | -1.29% | — | Stalk |
| Aug 22, 2025 | Sell | BDX | Michael Feld | EVP & President, Life Sciences | 57 | $197.99 | $43.6B | -25.77% | +12.89% | $11.3K | -0.68% | — | Stalk |
| Aug 20, 2025 | Sell | BDX | Michael Feld | EVP & President, Life Sciences | 773 | $199.20 | $43.6B | -25.77% | +12.89% | $154.0K | -8.41% | — | Stalk |
| Jul 18, 2025 | Buy | BDX | Michael David Garrison | EVP & President, Medical | 7,545 | $152.80 | $43.6B | -25.77% | +12.89% | $1.2M | +32.66% | — | Stalk |
| Jun 2, 2025 | Sell | BDX | David Shan | EVP and Chief ISC Officer | 1,166 | $171.19 | $43.6B | -25.77% | +12.89% | $199.6K | -20.31% | — | Stalk |
| Apr 9, 2025 | Sell | BDX | Michael David Garrison | EVP & President, Medical | 479 | $197.28 | $43.6B | -25.77% | +12.89% | $94.5K | -8.93% | — | Stalk |
| Apr 4, 2025 | Sell | BDX | Shana Carol Neal | EVP and Chief People Officer | 1,886 | $207.34 | $43.6B | -25.77% | +12.89% | $391.0K | -12.24% | — | Stalk |
| Mar 18, 2025 | Sell | BDX | Richard Byrd | EVP & President Interventional | 459 | $230.00 | $43.6B | -25.77% | +12.89% | $105.6K | -6.19% | — | Stalk |
| Mar 12, 2025 | Sell | BDX | Richard Byrd | EVP & President Interventional | 1,940 | $224.91 | $43.6B | -25.77% | +12.89% | $436.3K | -20.75% | — | Stalk |
| Mar 1, 2025 | Sell | BDX | Michael David Garrison | EVP & President Medical | 178 | $225.53 | $43.6B | -25.77% | +12.89% | $40.1K | -3.21% | — | Stalk |
| Jan 21, 2025 | Sell | BDX | David Shan | EVP and Chief ISC Officer | 500 | $240.00 | $43.6B | -25.77% | +12.89% | $120.0K | -8.01% | — | Stalk |
| Jan 21, 2025 | Sell | BDX | Shana Carol Neal | EVP and Chief People Officer | 787 | $240.00 | $43.6B | -25.77% | +12.89% | $188.9K | -4.86% | — | Stalk |
| Jan 17, 2025 | Sell | BDX | Michael David Garrison | EVP & President, Medical | 597 | $236.51 | $43.6B | -25.77% | +12.89% | $141.2K | -9.72% | — | Stalk |
| Jan 3, 2025 | Sell | BDX | David Shan | EVP and Chief ISC Officer | 44 | $228.46 | $43.6B | -25.77% | +12.89% | $10.1K | -0.70% | — | Stalk |
| Dec 19, 2024 | Sell | BDX | Michael David Garrison | EVP & President, Medical | 2,838 | $223.33 | $43.6B | -25.77% | +12.89% | $633.8K | -31.61% | — | Stalk |
| Dec 6, 2024 | Sell | BDX | Shana Carol Neal | EVP and Chief People Officer | 1,000 | $220.49 | $43.6B | -25.77% | +12.89% | $220.5K | -5.56% | — | Stalk |
| Dec 6, 2024 | Buy | BDX | Roland Goette | EVP and President, EMEA | 18,455 | $174.91 | $43.6B | -25.77% | +12.89% | $3.2M | +10.06% | — | Stalk |
| Dec 5, 2024 | Sell | BDX | David Shan | EVP and Chief ISC Officer | 1,500 | $220.25 | $43.6B | -25.77% | +12.89% | $330.4K | -19.27% | — | Stalk |
| Nov 26, 2024 | Sell | BDX | Pavan Kumar Mocherla | EVP & President Greater Asia | 20 | $224.25 | $43.6B | -25.77% | +12.89% | $4.5K | -0.32% | — | Stalk |
| Nov 26, 2024 | Sell | BDX | Pavan Kumar Mocherla | EVP & President, Greater Asia | 25 | $224.25 | $43.6B | -25.77% | +12.89% | $5.6K | -0.87% | — | Stalk |
| Nov 26, 2024 | Sell | BDX | David Shan | EVP and Chief ISC Officer | 124 | $224.25 | $43.6B | -25.77% | +12.89% | $27.8K | -1.01% | — | Stalk |
| Nov 26, 2024 | Sell | BDX | Roland Goette | EVP and President, EMEA | 196 | $224.25 | $43.6B | -25.77% | +12.89% | $44.0K | -1.01% | — | Stalk |
| Nov 26, 2024 | Sell | BDX | Michelle Quinn | EVP and General Counsel | 376 | $224.25 | $43.6B | -25.77% | +12.89% | $84.3K | -1.65% | — | Stalk |
| Nov 26, 2024 | Sell | BDX | Shana Carol Neal | EVP and Chief People Officer | 509 | $224.25 | $43.6B | -25.77% | +12.89% | $114.1K | -1.90% | — | Stalk |
| Nov 26, 2024 | Sell | BDX | Richard Byrd | EVP & President Interventional | 1,204 | $224.25 | $43.6B | -25.77% | +12.89% | $270.0K | -6.25% | — | Stalk |
| Nov 26, 2024 | Sell | BDX | Michael David Garrison | EVP & President, Medical | 1,230 | $224.25 | $43.6B | -25.77% | +12.89% | $275.8K | -6.09% | — | Stalk |
| Nov 26, 2024 | Sell | BDX | Antoine C Ezell | EVP, President Americas & CMO | 1,357 | $224.25 | $43.6B | -25.77% | +12.89% | $304.3K | -7.23% | — | Stalk |
| Nov 26, 2024 | Sell | BDX | Christopher Delorefice | EVP & Chief Financial Officer | 5,192 | $224.25 | $43.6B | -25.77% | +12.89% | $1.2M | -11.33% | — | Stalk |
| Nov 26, 2024 | Sell | BDX | Thomas E Jr Polen | Chairman, CEO and President | 23,564 | $224.25 | $43.6B | -25.77% | +12.89% | $5.3M | -12.75% | — | Stalk |
| Sep 7, 2024 | Sell | BDX | Christopher Delorefice | EVP & Chief Financial Officer | 466 | $232.67 | $43.6B | -25.77% | +12.89% | $108.4K | -3.51% | — | Stalk |
| Sep 1, 2024 | Sell | BDX | Richard Byrd | EVP & President Interventional | 216 | $242.41 | $43.6B | -25.77% | +12.89% | $52.4K | -3.44% | — | Stalk |
| Sep 1, 2024 | Sell | BDX | Christopher Delorefice | EVP & Chief Financial Officer | 254 | $242.41 | $43.6B | -25.77% | +12.89% | $61.6K | -1.88% | — | Stalk |
| Aug 14, 2024 | Buy | BDX | Roland Goette | EVP and President EMEA | 5,295 | $132.54 | $43.6B | -25.77% | +12.89% | $701.8K | +46.83% | — | Stalk |
| Jul 1, 2024 | Sell | BDX | Thomas J Spoerel | SVPController & Chief Acct Off | 48 | $229.27 | $43.6B | -25.77% | +12.89% | $11.0K | -2.43% | — | Stalk |
| Jun 10, 2024 | Sell | BDX | Thomas J Spoerel | SVP,Controller&Chief Acct Off | 300 | $239.31 | $43.6B | -25.77% | +12.89% | $71.8K | -13.18% | — | Stalk |
| May 15, 2024 | Sell | BDX | Roland Goette | EVP and President EMEA | 3,300 | $236.73 | $43.6B | -25.77% | +12.89% | $781.2K | -8.08% | — | Stalk |
| May 13, 2024 | Sell | BDX | Roland Goette | EVP and President EMEA | 3,300 | $236.70 | $43.6B | -25.77% | +12.89% | $781.1K | -6.77% | — | Stalk |
| Apr 30, 2024 | Sell | BDX | Michael David Garrison | EVP & President Medical | 1,715 | $232.81 | $43.6B | -25.77% | +12.89% | $399.3K | -24.17% | — | Stalk |
| Apr 4, 2024 | Sell | BDX | Shana Carol Neal | EVP and Chief People Officer | 1,921 | $243.05 | $43.6B | -25.77% | +12.89% | $466.9K | -10.49% | — | Stalk |
| Mar 14, 2024 | Sell | BDX | Thomas J Spoerel | SVP,Controller&Chief Acct Off | 282 | $238.29 | $43.6B | -25.77% | +12.89% | $67.2K | -11.02% | — | Stalk |
| Mar 1, 2024 | Sell | BDX | Thomas J Spoerel | SVP,Controller&Chief Acct Off | 36 | $235.31 | $43.6B | -25.77% | +12.89% | $8.5K | -1.39% | — | Stalk |
| Mar 1, 2024 | Sell | BDX | Michael David Garrison | EVP & President Medical | 178 | $235.31 | $43.6B | -25.77% | +12.89% | $41.9K | -2.45% | — | Stalk |
| Mar 1, 2024 | Sell | BDX | Antoine C Ezell | EVP, President NA & CMO | 282 | $235.31 | $43.6B | -25.77% | +12.89% | $66.4K | -2.94% | — | Stalk |
| Jan 3, 2024 | Sell | BDX | David Shan | EVP and Chief ISC Officer | 44 | $240.47 | $43.6B | -25.77% | +12.89% | $10.6K | -0.77% | — | Stalk |
| Dec 11, 2023 | Sell | BDX | Michael David Garrison | EVP & President Medical | 1,239 | $232.46 | $43.6B | -25.77% | +12.89% | $288.0K | -14.55% | — | Stalk |
| Nov 28, 2023 | Sell | BDX | Richard Byrd | EVP & President Interventional | 2,156 | $238.47 | $43.6B | -25.77% | +12.89% | $514.1K | -34.35% | — | Stalk |
| Nov 26, 2023 | Sell | BDX | Pavan Kumar Mocherla | EVP & President Greater Asia | 64 | $238.89 | $43.6B | -25.77% | +12.89% | $15.3K | -1.38% | — | Stalk |
| Nov 26, 2023 | Sell | BDX | David Shan | EVP and Chief ISC Officer | 149 | $238.89 | $43.6B | -25.77% | +12.89% | $35.6K | -1.42% | — | Stalk |
| Nov 26, 2023 | Sell | BDX | Roland Goette | EVP and President EMEA | 213 | $238.89 | $43.6B | -25.77% | +12.89% | $50.9K | -0.98% | — | Stalk |
| Nov 26, 2023 | Sell | BDX | Shana Carol Neal | EVP and Chief People Officer | 258 | $238.89 | $43.6B | -25.77% | +12.89% | $61.6K | -0.93% | — | Stalk |
| Nov 26, 2023 | Sell | BDX | Thomas J Spoerel | SVPController & Chief Acct Off | 365 | $238.89 | $43.6B | -25.77% | +12.89% | $87.2K | -6.48% | — | Stalk |
| Nov 26, 2023 | Sell | BDX | Michelle Quinn | EVP and General Counsel | 440 | $238.89 | $43.6B | -25.77% | +12.89% | $105.1K | -3.64% | — | Stalk |
| Nov 26, 2023 | Sell | BDX | Christopher Delorefice | EVP & Chief Financial Officer | 812 | $238.89 | $43.6B | -25.77% | +12.89% | $194.0K | -2.48% | — | Stalk |
| Nov 26, 2023 | Sell | BDX | Richard Byrd | EVP & President Interventional | 1,509 | $238.89 | $43.6B | -25.77% | +12.89% | $360.5K | -9.52% | — | Stalk |
| Nov 26, 2023 | Sell | BDX | Michael David Garrison | EVP & President Medical | 1,646 | $238.89 | $43.6B | -25.77% | +12.89% | $393.2K | -8.02% | — | Stalk |
| Nov 26, 2023 | Sell | BDX | Antoine C Ezell | EVP, President NA & CMO | 1,654 | $238.89 | $43.6B | -25.77% | +12.89% | $395.1K | -9.99% | — | Stalk |
| Nov 16, 2023 | Buy | BDX | Roland Goette | EVP and President, EMEA | 3,544 | $107.12 | $43.6B | -25.77% | +12.89% | $379.6K | +26.02% | — | Stalk |
| Sep 7, 2023 | Sell | BDX | Christopher Delorefice | EVP & Chief Financial Officer | 601 | $267.06 | $43.6B | -25.77% | +12.89% | $160.5K | -5.18% | — | Stalk |
| Sep 5, 2023 | Sell | BDX | Richard Byrd | EVP & President Interventional | 459 | $274.48 | $43.6B | -25.77% | +12.89% | $126.0K | -11.76% | — | Stalk |
| Sep 1, 2023 | Sell | BDX | Richard Byrd | EVP & President Interventional | 216 | $278.46 | $43.6B | -25.77% | +12.89% | $60.1K | -5.24% | — | Stalk |
| Sep 1, 2023 | Sell | BDX | Christopher Delorefice | EVP & Chief Financial Officer | 353 | $278.46 | $43.6B | -25.77% | +12.89% | $98.3K | -2.95% | — | Stalk |
| Aug 11, 2023 | Buy | BDX | David Hickey | EVP & President, Life Sciences | 6,857 | $195.56 | $43.6B | -25.77% | +12.89% | $1.3M | +7.38% | — | Stalk |
| Aug 8, 2023 | Sell | BDX | Michael David Garrison | EVP & President Medical | 1,300 | $277.13 | $43.6B | -25.77% | +12.89% | $360.3K | -20.13% | — | Stalk |